Clindamycin-Hydrochloride shortage — AU supply status & alternatives

Clindamycin-Hydrochloride

ATC D10AF01

Anticipated · Australia

APO-CLINDAMYCIN Clindamycin

Anticipated · 🇦🇺 Australia

Anticipated shortage

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

Sept 2026

Sponsor est. via TGA

Product attributes reference data we hold

ATC level 5
Active ingredient (INN)	Clindamycin-Hydrochloride
Brand names	APO-CLINDAMYCIN Clindamycin

ATC level 4	D10AF

Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Recalls official enforcement reports

🇺🇸

Clindamycin Hcl

RemedyRepack Inc. · Mar 2025

Class IIdetails ↗

🇺🇸

Clindamycin And Benzoyl Peroxide Gel

TOLMAR, Inc. · Nov 2021

Class IIdetails ↗

🇺🇸

Clindamycin Injection

Pfizer Inc. · Mar 2019

Class IIIdetails ↗

🇺🇸

Clindamycin Injection

Pfizer Inc. · Mar 2019

Class IIIdetails ↗

🇺🇸

Clindamycin Injection

Pfizer Inc. · Mar 2019

Class IIIdetails ↗

🇺🇸

Clindamycin Phosphate Usp For Prescription Compounding

American Pharmaceutical Ingredients LLC · Feb 2018

Class IIdetails ↗

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.